Smith Chas P & Associates PA Cpas Sells 683 Shares of Eli Lilly and Company $LLY

Smith Chas P & Associates PA Cpas trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 56.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 520 shares of the company’s stock after selling 683 shares during the period. Smith Chas P & Associates PA Cpas’ holdings in Eli Lilly and Company were worth $397,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $487,000. Central Pacific Bank Trust Division boosted its position in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after buying an additional 1,843 shares during the period. Cidel Asset Management Inc. increased its position in Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after acquiring an additional 5,591 shares during the period. Finally, Oak Family Advisors LLC bought a new position in shares of Eli Lilly and Company during the third quarter valued at $1,979,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on LLY shares. HSBC restated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Argus raised their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Shareholders of Ventyx Biosciences approved a merger with Eli Lilly, clearing an acquisition that expands Lilly’s biologics/pipeline footprint and signals continued M&A-driven growth. Ventyx Biosciences Shareholders Approve Merger With Eli Lilly
• Positive Sentiment: Eli Lilly says it is preparing to launch its oral obesity drug orforglipron in the U.S. as soon as Q2 if FDA approval comes — a potential multi‑billion dollar new product that’s central to revenue expectations. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: CHMP has backed expanded use of Olumiant for adolescents with severe alopecia areata, moving the EU approval decision closer and potentially broadening an existing product’s market. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Lilly advanced remternetug clinical testing in China for Alzheimer’s, extending its geographic and therapeutic reach in neuroscience — positive for long‑term pipeline value in a high‑need area. Lilly Advances Remternetug Testing in China, Extending Its Alzheimer’s Pipeline Reach
• Positive Sentiment: Lilly reported a Phase 1 update advancing a new oral diabetes candidate in China — further international development that could support future launches and address diabetes market demand. Eli Lilly Advances New Oral Diabetes Drug In China: What Investors Should Watch
• Neutral Sentiment: Coverage and commentary (Zacks/Yahoo/analysis pieces) highlight strong recent gains but warn momentum has cooled and valuation is rich — important context for near‑term trader flows and analyst expectations. Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Competitor risk: Novo Nordisk is expanding manufacturing in Ireland to strengthen oral GLP-1 supply — a move that could intensify competition in the obesity/diabetes market where Lilly is targeting major growth. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
• Negative Sentiment: Some retail/analyst commentary argues investors should consider other large-cap pharma names instead of Lilly given valuation and competition — adds short‑term negative sentiment even if longer‑term thesis stays intact. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lilly and Company Stock Down 1.0%

LLY stock opened at $1,007.37 on Wednesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock’s 50 day simple moving average is $1,050.71 and its 200 day simple moving average is $936.44. The company has a market cap of $950.31 billion, a P/E ratio of 43.89, a price-to-earnings-growth ratio of 1.18 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the company earned $5.32 EPS. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.